Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00385788 · ClinicalTrials.gov registry record · Phase 2
Allogeneic Blood Stem Cell Transplantation and Adoptive Immunotherapy for Hodgkin's Disease
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 52
- Enrollment target
NCT00385788: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00385788 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 52 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00385788, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 52 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if fludarabine, melphalan and gemcitabine followed by transplantation of stem cells (blood-forming cells) as well as immune cells (lymphocytes), collected from a matched related (i.e. a sibling) or unrelated donor, or a mismatched related donor, can help to control Hodgkin's disease. The safety of the treatment will also be studied.
Interventions
- DRUG Fludarabine
- DRUG Melphalan
- DRUG Gemcitabine
- PROCEDURE Allogeneic Stem Cell Infusion
- DRUG Antithymocyte Globulin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2005-07 |
| Est. Completion | 2016-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00385788
The ClinicalTrials.gov registry entry for NCT00385788 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Fludarabine is the first listed.
NCT00385788 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00385788 about?
NCT00385788 is a clinical study titled "Allogeneic Blood Stem Cell Transplantation and Adoptive Immunotherapy for Hodgkin's Disease". The goal of this clinical research study is to learn if fludarabine, melphalan and gemcitabine followed by transplantation of stem cells (blood-forming cells) as well as immune cells (lymphocytes), collected from a matched related (i.e. a sibling) or unrelated donor, or a mismatched related donor, c...
What is the current status of trial NCT00385788?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 2005-07. Estimated completion is 2016-08.
What interventions are being tested in trial NCT00385788?
The interventions under investigation include: Fludarabine (DRUG), Melphalan (DRUG), Gemcitabine (DRUG), Allogeneic Stem Cell Infusion (PROCEDURE), Antithymocyte Globulin (DRUG).
Who is sponsoring clinical trial NCT00385788?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.